Applied DNA Sciences Files 8-K on Security Holder Votes
Ticker: BNBX · Form: 8-K · Filed: Aug 2, 2024 · CIK: 744452
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: APDN
TL;DR
APDN filed an 8-K on Aug 2nd about shareholder votes - check for key decisions.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on August 2, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and decisions made during this period.
Why It Matters
This filing provides transparency into key decisions and votes made by Applied DNA Sciences' security holders, which can impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and does not inherently present new financial or operational risks.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- August 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 50 Health Sciences Drive Stony Brook, New York 11790 (address) — Principal executive office
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 2, 2024.
What is the principal executive office address of Applied DNA Sciences, Inc.?
The principal executive office address is 50 Health Sciences Drive, Stony Brook, New York 11790.
In which state was Applied DNA Sciences, Inc. incorporated?
Applied DNA Sciences, Inc. was incorporated in Delaware.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number for Applied DNA Sciences, Inc. is 001-36745.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-08-02 16:30:19
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm2420716d1_8k.htm (8-K) — 23KB
- 0001104659-24-085391.txt ( ) — 190KB
- apdn-20240802.xsd (EX-101.SCH) — 3KB
- apdn-20240802_lab.xml (EX-101.LAB) — 33KB
- apdn-20240802_pre.xml (EX-101.PRE) — 22KB
- tm2420716d1_8k_htm.xml (XML) — 3KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 2, 2024, Applied DNA Sciences, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, an aggregate of 4,056,202 shares of the Company's common stock ("Common Stock") were present in person or by proxy and entitled to vote, which did not constitute a quorum determined in accordance with the Company's By-Laws, which requires a majority of the Company's issued and outstanding shares of Common Stock. Accordingly, no action was taken with respect to the proposal presented at the Special Meeting, and the Special Meeting was adjourned. As previously reported on its Form 8-K filed on May 29, 2024, the Company closed on such date a public offering of common stock and series A and B common stock purchase warrants (the "Series Warrants"). The Series Warrants will only be exercisable upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (the "Warrant Stockholder Approval"). Further, pursuant to the terms of the Series Warrants, since the Company did not obtain Warrant Stockholder Approval at the Special Meeting, it is obligated to call a subsequent stockholder meeting to seek to obtain Warrant Stockholder Approval.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 2, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: President and Chief Executive Officer